Adverse Drug Reaction Classification System

ADR Ontology
ADR Term Keratoacanthoma
ADR ID BADD_A02442
ADR Hierarchy
16      Neoplasms benign, malignant and unspecified (incl cysts and polyps)
16.03      Skin neoplasms malignant and unspecified
16.03.02      Skin neoplasms malignant and unspecified (excl melanoma)
16.03.02.007      Keratoacanthoma
23      Skin and subcutaneous tissue disorders
23.08      Skin neoplasms malignant and unspecified
23.08.02      Skin neoplasms malignant and unspecified (excl melanoma)
23.08.02.007      Keratoacanthoma
Description A benign, non-neoplastic, usually self-limiting epithelial lesion closely resembling squamous cell carcinoma clinically and histopathologically. It occurs in solitary, multiple, and eruptive forms. The solitary and multiple forms occur on sunlight exposed areas and are identical histologically; they affect primarily white males. The eruptive form usually involves both sexes and appears as a generalized papular eruption. [MeSH]
MedDRA Code 10023347
MeSH ID D007636
ADR Severity Grade (FAERS)
ADR Severity Grade (CTCAE) Not Available
Synonym
Keratoacanthoma | Squamous cell carcinoma, keratoacanthoma-type | Keratoacanthomas
ADR Related Proteins
Protein Name UniProt AC TTD Target ID
Not AvailableNot AvailableNot Available
Drugs Leading to the ADR
Drug IDDrug NameADR Frequency (FAERS)ADR Severity Grade (FAERS)
BADD_D00156Apremilast0.002316%
BADD_D00566Dabrafenib0.001332%
BADD_D00567Dabrafenib mesylate--
BADD_D00589Dasatinib0.000533%
BADD_D00931Fluorouracil0.001411%
BADD_D01158Ingenol mebutate0.019598%
BADD_D01252Leflunomide0.002066%
BADD_D01253Lenalidomide--
BADD_D01858Propagermanium--
BADD_D01922Regorafenib--
BADD_D02058Sorafenib0.000533%
BADD_D02344Vemurafenib0.011477%
BADD_D02365Vismodegib0.000533%
The 1th Page    1    Total 1 Pages